Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 7/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29129944 | 1.00 | GAA (0.42) | GAACRBNEPHX2NFKB1NFKB2 | |
| SCHEMBL29129943 | 1.00 | GAA (0.42) | GAACRBNEPHX2NFKB1NFKB2 | |
| SCHEMBL29675291 | 0.83 | EPHX2 (0.44) | GAACRBNEPHX2RIPK1SCN9A | |
| SCHEMBL22527358 | 0.83 | EPHX2 (0.44) | GAACRBNEPHX2RIPK1SCN9A | |
| SCHEMBL803714 | 0.83 | GAA (0.40) | GAAEPHX2NFKB1NFKB2RELA | |
| SCHEMBL27001903 | 0.83 | CRBN (0.43) | CRBNRIPK1DDB1 | |
| SCHEMBL27133713 | 0.83 | CRBN (0.43) | CRBNRIPK1DDB1 | |
| SCHEMBL25764042 | 0.82 | GAA (0.41) | GAACRBNEPHX2RIPK1AAK1 | |
| SCHEMBL17321319 | 0.81 | BACE1 (0.44) | GAAEPHX2RIPK1BACE1AAK1 | |
| SCHEMBL1269024 | 0.79 | RIPK1 (0.52) | GAAEPHX2RIPK1BACE1AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12156880-B2 | Heterocyclic RIP1 kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2024-12-03 | — | — | US | disclosed |
| EP-4304713-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| US-20220296608-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | MIDCAP FINANCIAL TRUST | 2022-09-22 | — | — | US | disclosed |
| WO-2022192533-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2022-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220296608-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | RIPK1, RIPK2, RIPK3 | GAA 1632/4885CRBN 2510/4885EPHX2 3597/4885 |
| US-12156880-B2 | Heterocyclic RIP1 kinase inhibitors | RIPK1, RIPK2, RIPK3 | GAA 1632/4885CRBN 2510/4885EPHX2 3597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.